title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Supporting information | PMC9974128 | |||
Table 1 medicare benefits schedule categories. | (DOCX)Click here for additional data file. | PMC9974128 | ||
Fig 1 proportion of the study sample who utilised government funded medical services as classified by the 2020 medicare benefits schedule. | (DOCX)Click here for additional data file. | PMC9974128 | ||
Fig 2 proportion of the study sample who were supplied with government-subsidised medicines categorised according to the World Health Organisation Anatomical Therapeutic Chemical (ATC) classification system. | (DOCX)Click here for additional data file. | PMC9974128 | ||
Table 6 association between clinico-demographics and mean total healthcare costs. | (DOCX)Click here for additional data file. | PMC9974128 | ||
Table 7 association between clinico-demographics and mean total MBS and PBS costs. | Cancer | CANCER | (DOCX)Click here for additional data file.The authors are indebted to the people who participated in this research. We acknowledge members of the trial’s Executive Committee responsible for overseeing the project, including: Prof Melanie Lovell (Chair), Prof Meera Agar, Dr. Tim Luckett and Prof Jane Phillips. We acknow... | PMC9974128 |
References | PMC9974128 | |||
Subject terms | IDA | IRON DEFICIENCY ANEMIA, EVENTS, SECONDARY, ADVERSE EVENTS | In patients on chronic hemodialysis, there is no standard protocol for maintenance iron supplementation. This study aimed to compare two fixed-dose intravenous (IV) iron protocols to reduce erythropoiesis-stimulating agents (ESA). We conducted a double-blinded, randomized controlled study on hemodialysis patients havin... | PMC9870895 |
Introduction | death, IDA | ADVERSE EFFECTS, IRON DEFICIENCY ANEMIA | Iron deficiency anemia (IDA) remains a major problem in chronic hemodialysis patientsThe PIVOTAL trialOur aim was to find appropriate doses of maintenance iron therapy. Therefore, we conducted a randomized controlled trial to compare the efficacy of 100 mg IV iron with 200 mg IV iron per month regimens to minimize mont... | PMC9870895 |
Methods | PMC9870895 | |||
Trial design | infection, death | RENAL, INFECTION, KIDNEY, ADVERSE EVENTS | A single-center, double-blinded, post-hoc superiority, randomized controlled trial was conducted at Thammasat University Hospital from July 2019 to February 2021. The trial protocol was approved by the Human Research Ethics Committee of Thammasat University No 1 (Faculty of Medicine): MTU-EC-OO-4-055/62 and followed th... | PMC9870895 |
Participants | infection, malignancy, HIV or hepatitis B or C infection, heart failure | HYPERSENSITIVITY REACTION, HEMATOLOGIC MALIGNANCY, INFECTION, END-STAGE RENAL DISEASE, HEART FAILURE, CHRONIC LIVER DISEASE | Adults ≥ 18 years old with end-stage renal disease, undergoing chronic hemodialysis > 90 days were enrolled in this study. Other eligibility criteria were those with a ferritin level of 200–700 ng/dl, TSAT of 20–40%, Hb > 9 g/dl, and received ESA regularly. Exclusion criteria were life expectancy < 6 months, those plan... | PMC9870895 |
Outcomes | thrombosis, death, IDA | THROMBOSIS, MYOCARDIAL INFARCTION, STROKE | The primary efficacy endpoint was to compare mean monthly doses of ESA at month 12 between the two groups. Secondary efficacy endpoints were the incidence of death, myocardial infarction, stroke, IDA, blood transfusion, quality of life, and changes in Hb, ferritin levels, TSAT, and ESA doses.Safety parameters were eval... | PMC9870895 |
Statistical analyses | According to the PIVOTAL trialContinuous variables were expressed as mean ± standard deviation (SD) or median and IQR and compared using unpaired We presented time to withholding IV iron and time to iron rescue therapy between groups using the Kaplan–Meier curve and compared it with Cox proportional hazard models. Mean... | PMC9870895 | ||
Results | PMC9870895 | |||
Discussion | thrombosis | THROMBOSIS, HAND INFECTION, CHRONIC BLOOD LOSS, ADVERSE EVENTS, EVENT, ADVERSE EFFECTS, EVENTS, OXIDATIVE STRESS | Our study shows that maintenance IV iron at higher doses (200 mg vs. 100 mg) was more effective in reducing ESA doses at month 12. However, the incidence of absolute IDA was significantly higher in the 100-mg IV iron group. Nevertheless, iron therapy was withheld significantly more often in the 200-mg IV iron group. Th... | PMC9870895 |
Supplementary Information | The online version contains supplementary material available at 10.1038/s41598-023-28440-3. | PMC9870895 | ||
Acknowledgements | RENAL, KIDNEY | This study is supported by the Kidney Foundation of Thailand and the Research Group in Nephrology and Renal Replacement Therapy from the Faculty of Medicine, Thammasat University. One of the ESA supplies, Hypercrit®, was partially supported by Comsa Medical Company Limited and Biosidus S.A. We would like to thank all p... | PMC9870895 | |
Author contributions | S.A. and P.T. designed the study. S.A. and A.C. collected data. P.T. performed the analyses and made the figures. All the authors interpreted and gave suggestions for additional analyses. S.A. and P.T. wrote the manuscript. All the authors reviewed and approved the final version of the manuscript. | PMC9870895 | ||
Funding | RENAL, KIDNEY | The Kidney Foundation of Thailand; Research Group in Nephrology and Renal Replacement Therapy, Faculty of Medicine, Thammasat University. | PMC9870895 | |
Data availability | The datasets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request. | PMC9870895 | ||
Competing interests | The authors declare no competing interests. | PMC9870895 | ||
References | PMC9870895 | |||
Subject terms | COLD | The Wim Hof method (WHM) is a multi-disciplinary approach to physical and mental well-being combining cold exposure, breathing exercises, and meditation. This study evaluated the effects of a 15 days WHM intervention on cardiovascular parameters at rest and during a cold pressor test (CPT), as well as on various psycho... | PMC10579249 | |
Introduction | CVDs, Cardiovascular diseases, anxiety, inflammation, , reduced stress | CARDIOVASCULAR DISEASE, CARDIOVASCULAR DISEASE, INFLAMMATION, CARDIOVASCULAR MORBIDITY, COLD | Cardiovascular diseases (CVDs) are a major cause of morbidity and mortality worldwideMindfulness-based interventions aim to reduce blood pressure (BP) by employing stress-reduction techniques, including meditation, which are designed to foster a state of inner awareness and calmnessCold water immersion is hypothesized ... | PMC10579249 |
Methods | PMC10579249 | |||
Study design and participants | pain | MAY, COLD | This study was designed as a randomized controlled trial with parallel arms. Participants were recruited between May and July 2022 through social media and personal contacts. Eligibility criteria included (1) being male, (2) having no underlying health conditions, (3) not using antihypertensive or other cardiovascular ... | PMC10579249 |
Measurements | PMC10579249 | |||
Anthropometrics | CREST | Height and body mass were assessed using a stadiometer and scale (BC-545 Innerscan, Tanita, Netherlands). Waist circumference was measured to the nearest 0.1 cm at the midpoint between the iliac crest and the lowest ribs. Body Mass Index (BMI) was calculated as body mass in kilograms divided by height in meters squared... | PMC10579249 | |
Physical activity | Self-reported physical activity was assessed using a modified version of the Godin-Shephard Leisure-Time Physical Activity Questionnaire,a valid and reliable tool for assessing physical activity | PMC10579249 | ||
Heart rate variability | HRV was measured using a Polar RS800 CX | PMC10579249 | ||
Blood pressure | Systolic BP, diastolic BP, and PWV were obtained non-invasively using the Mobil-O-Graph | PMC10579249 | ||
Cold pressor test | pain | COLD | The cold pressor test is a common and extensively validated test for assessing cardiovascular reactivity. Trained study staff performed the cold pressor test before and after the intervention using a standardized protocol. Before the test, the participants rested in a supine position and had their BP, PWV, and HR measu... | PMC10579249 |
Perceived stress | The Perceived Stress Scale (PSS) by Cohen et al. | PMC10579249 | ||
Affect | POSITIVE | The Positive and Negative Affect Schedule (PANAS) | PMC10579249 | |
Vitality | The Subjective Vitality Scale (SVS) | PMC10579249 | ||
Intervention | PMC10579249 | |||
Wim Hof method | The intervention followed the guidelines provided by Wim HofAt the end of the baseline assessments, the participants received oral step-by-step instructions from the study staff, who were experienced in the WHM, on how to perform the various intervention components. They also received written instructions providing a s... | PMC10579249 | ||
Breathing-method | The breathing exercises consisted of a specific sequence of deep breaths in, holds, and breaths out, performed in a cyclic manner. The participants were provided with guided audio instructions. Participants were instructed to sit or lay in a comfortable position and perform 30 to 40 conscious breaths, inhaling deeply i... | PMC10579249 | ||
Meditation | The meditation component of the WHM is a mindfulness-based technique that aims to regulate emotions and thoughts. Participants were instructed to find a quiet place, sit, or lie down in a comfortable position and focus their attention on their breathing and their body sensations. They were encouraged to pay attention t... | PMC10579249 | ||
Cold-water exposure | COLD | The cold-water exposure component involved exposure to cold water in the form of cold showers. Participants were instructed to take shower in cold water for a set period of time, starting with 30 s, and increase the time each day by 5 s as they become acclimated. The participants received an MP3 file that emitted a sou... | PMC10579249 | |
Statistics | Data analysis was conducted using IBM SPSS Statistics for Windows, Version 27.0 (IBM Corp., Armonk, NY, USA). The normal distribution of the data was checked using the Kolmogorov–Smirnov test. Independent samples t-test was applied to examine differences in baseline measures between the groups. To analyze the effect of... | PMC10579249 | ||
Results | illness, hypertensive | ADVERSE EVENTS | One participant in the IG dropped out due to illness. In total, 21 participants in the IG and 20 participants in the CG were included in the final analysis. The age range was between 18 and 39 years. No adverse events occurred during the intervention period in any of the participants. The subject’s characteristics are ... | PMC10579249 |
Cardiovascular parameters | pain | No significant time × group interactions could be detected in HR (F(1,39) = 0.14, Changes in cardiovascular outcomes, perceived pain, and MET hours from before to after intervention for the intervention group (IG) and control group (CG).Data expressed as means ± standard deviations. No main effects for time could be de... | PMC10579249 | |
Cold pressor test | COLD | No significant time × group interactions could be detected in the stress response to the cold pressor test in ΔHR (F(1,39) = 0.29, Again no main effect for time could be detected in ΔHR (F(1,39) = 0.002, | PMC10579249 | |
Psychological parameters | There were no significant time × group interactions for PANAS+ (F(1,38) = 0.65, Changes in psychological outcomes from before to after intervention for the intervention group (IG) and control group (CG).Data expressed as means ± standard deviations. Only the PSS revealed a significant main effect for time (F(1,38) = 1... | PMC10579249 | ||
Discussion | The present study aimed to determine the effectiveness of the WHM on various psychological and physiological parameters. No significant time × group interaction could be detected for any of the outcomes. Thus, contrary to the claim by Wim Hof | PMC10579249 | ||
Cardiovascular parameters | COLD | Unfortunately, there are no comparable studies assessing the effects of the WHM on cardiovascular parameters. However, previous studies on the different components of the WHM can inform the interpretation of the results.It has been often proposed that regular cold exposure may possibly comprise a healthier cardiovascul... | PMC10579249 | |
Cardiovascular reactivity | pain | COLD | Previous research has demonstrated that cold water immersion stimulates positive adaptive changes in the human body, resulting in increased readiness to handle stress factorsWe postulated that regular cold exposure could mitigate the vasoconstrictive effects of acute cold exposure, thereby reducing the cardiovascular r... | PMC10579249 |
Meditation | Besides cold-water immersion, also meditation techniques have been reported to lower BP and improve HRV in older or at-risk patientsIn the present study, the WHM, which includes a meditation component, could not induce changes in HR, HRV, BP, and PWV. It's worth noting that the intervention period in the present study ... | PMC10579249 | ||
Breathing | COLD | Slow deep breathing, commonly practiced in meditation, yoga, and several relaxation techniques, has been shown to positively affect BPRecent studies by Zwaag et al.Unfortunately, there are no studies on the long-term effects of this breathing technique on HR, HRV, BP, and PWV. According to the results of the present st... | PMC10579249 | |
Psychological parameters | The present study did not detect any significant changes in affect (positive and negative), vitality, and perceived stress after regularly performing the WHM.To the best of our knowledge, no previous studies have addressed the effects of regularly performing the WHM on these psychological outcomes. Only, Petraskova et ... | PMC10579249 | ||
Limitations | hyperventilation | COLD | Several limitations of this study must be addressed. First, the study only included healthy young male adults, which may limit the generalizability of the results to other populations, such as individuals with a higher risk profile or female participants. Second, the home-based intervention did not allow for standardiz... | PMC10579249 |
Conclusion | mood, reduced stress | The WHM has gained popularity for its potential health and performance benefits, including performance enhancement, improved mood, reduced stress, enhanced immune function, improved cardiovascular function, and increased vitalityFurther studies should address the effects of a longer and more intense intervention, and s... | PMC10579249 | |
Acknowledgements | We would like to thank all participants for taking part in this study. | PMC10579249 | ||
Author contributions | S.K. conceived the original idea, designed the study, processed the experimental data, performed the analysis, and drafted the manuscript. C.R.N. supervised the project, aided in interpreting the results, and worked on the manuscript. D.Q., X.B., X.M., E.B. performed the measurements, processed the experimental data, a... | PMC10579249 | ||
Data availability | All raw data are available on request to the corresponding author. | PMC10579249 | ||
Competing interests | The authors declare no competing interests. | PMC10579249 | ||
References | PMC10579249 | |||
1. Introduction | critically ill, dyspnea, ARDS, infection, pulmonary and cardiovascular adverse | VIRUS, CRITICALLY ILL, ARDS, INFECTION, CORONAVIRUS, SEVERE ACUTE RESPIRATORY SYNDROME, ACUTE RESPIRATORY DISTRESS SYNDROME, COMPLICATIONS | Administering N-acetylcysteine (NAC) could counteract the effect of free radicals, improving the clinical evolution of patients admitted to the Intensive Care Unit (ICU). This study aimed to investigate the clinical and biochemical effects of administering NAC to critically ill patients with COVID-19. A randomized cont... | PMC10181318 |
2. Materials and Methods | PMC10181318 | |||
2.1. Patients and Study Design | critically ill | CRITICALLY ILL | A randomized, controlled clinical trial was conducted on critically ill patients with COVID-19. The design was a prospective, analytical, follow-up study of cases and controls. The sample of patients studied was made up of 140 consecutive patients over 18 years of age (women, 23.6%) admitted to the ICU with COVID-19. T... | PMC10181318 |
2.2. Treatment and Nutritional Support | Patients received treatment that included medications (antivirals, antibacterial, corticosteroids, etc.), respiratory support, and nutritional support (enteral, parenteral, and/or mixed enteral/parenteral) during the hospital stay. The latter was according to the Clinical Nutrition Units Guidelines of the hospitals, ba... | PMC10181318 | ||
2.3. NAC Intervention | The intravenous dosage schedule was based on that used in acute paracetamol poisoning. The NAC administration protocol was based on the Prescott et al. protocol [ | PMC10181318 | ||
2.4. Data Collection | On the day of ICU admission and on the third day, the following data were recorded: patient age, sex, Acute Physiology and Chronic Health Assessment II (APACHE II) score [ | PMC10181318 | ||
2.5. Biochemical Parameters | Initial and final plasma and erythrocyte samples were collected under fasting conditions, followed by centrifugation (4 °C for 15 min at 3500 rpm) to separate plasma and serum. The samples were stored at −80 °C before biochemical analysis for subsequent tests. Plasma and erythrocyte samples were obtained from the NAC-t... | PMC10181318 | ||
2.6. Assessment of GSH and GSSG | COLD | A colorimetric detection kit (Invitrogen by Thermofisher Scientific, ref: EIAGSHC, Madrid, Spain) was used to perform the GSH and GSSG determination assay. The erythrocyte samples were treated with sulfosalicylic acid to precipitate the proteins. Thereafter, 0.050 mL of the sample was placed in an Eppendorf tube and 0.... | PMC10181318 | |
2.7. Assessment of Erythrocyte Glutathione Peroxidase Activity (GPx1 Activity) | The GPx1 activity of red blood cell hemolysate was assessed with a colorimetric assay using the Bioxytech | PMC10181318 | ||
2.8. Statistical Analysis | Statistical analysis was performed with SPSS version 21.0 for Windows (SPSS Inc., Chicago, IL, USA). Qualitative variables were presented as frequencies and percentages of patients, and quantitative variables as mean ± standard deviation (SD). For continuous variables, the assumption of normality was tested using the S... | PMC10181318 | ||
3. Results | PMC10181318 | |||
4. Discussion | DISEASE, COVID-19 PNEUMONIA, OXIDATIVE STRESS | The main results of the present study revealed that in NAC-treated patients, PaOIn our study, both the NAC-treated and control group patients had an altered clinical outcome on the first day of the study. Moreover, a decrease in the positive end-expiratory pressure (PEEP) and an increase in PaOThe CRP, D-dimer, and LDH... | PMC10181318 | |
5. Conclusions | critically ill, ill | CRITICALLY ILL | The administration of NAC manages to improve the clinical and analytical response of seriously ill patients with COVID-19 compared to the control group. NAC is able to stop the decrease in glutathione concentrations. Therefore, the administration of NAC in critically ill patients with COVID-19 could be assessed based o... | PMC10181318 |
Author Contributions | Conceptualization, Y.G.-M., J.C.-P. and E.P.; Methodology, Y.G.-M., J.F.M.-C., J.C.-P., J.M.P.-V. and E.P.; Software, Y.G.-M., L.H.-Q., J.F.M.-C. and H.V.-L.; Validation, Y.G.-M., J.M.-L. and E.P.; Formal analysis, Y.G.-M.; Investigation, L.H.-Q., H.V.-L., J.F.M.-C., J.C.-P. and J.M.P.-V.; Resources, E.P. and J.M.-L.; ... | PMC10181318 | ||
Institutional Review Board Statement | The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the University of Granada (protocol code 149/CEIH/2016). | PMC10181318 | ||
Informed Consent Statement | Informed consent was obtained from all subjects involved in the study. | PMC10181318 | ||
Data Availability Statement | Data will be shared upon reasonable request by the corresponding author: Yenifer Gamarra-Morales. | PMC10181318 | ||
Conflicts of Interest | The authors declare no conflict of interest. | PMC10181318 | ||
1. Introduction | oxaliplatin-induced, breast cancer, CIPN, neurotoxic, Cancer | SIDE EFFECT, BREAST CANCER, ADVERSE EVENT, CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY, CANCER | Chemotherapy-induced peripheral neuropathy (CIPN) is a serious side effect of weekly paclitaxel-based chemotherapy for breast cancer, that can persist for years. Cryotherapy therapy is effective for preventing early CIPN, but its protective effect on persistent CIPN is uncertain. This is a cross-sectional study conduct... | PMC10118320 |
2. Materials and Methods | PMC10118320 | |||
2.1. Study design and participants | CIPN, breast cancer | BREAST CANCER | This cross-sectional study was conducted performed as adjunct to a randomized trial evaluating the preventive effect of cryotherapy on weekly paclitaxel-induced CIPN in breast cancer patients (UMIN000034966). The original randomized trial detailed information and results are described in a previous report. | PMC10118320 |
2.2. Evaluation of CIPN | CIPN, Cancer | PERIPHERAL NEUROPATHY, CANCER | Eligible patients were assessed for early and persistent CIPN using a questionnaire survey for Functional Assessment of Cancer Therapy-Neurotoxicity (FACT-NTX) score at treatment completion (evaluated as early CIPN) and more than 1 year after treatment completion (evaluated as persistent CIPN). Briefly, FACT-NTX has 11... | PMC10118320 |
2.3. Statistical analysis | Groups assessed patient characteristics using a Fisher exact test for categorical variables and a | PMC10118320 | ||
3. Results | PMC10118320 | |||
3.1. Patient characteristics | TNBC, neurotoxic, cancer therapy-neurotoxicity | TRIPLE NEGATIVE BREAST CANCER, RECURRENT BREAST CANCER | Of the 44 patients enrolled in the previous randomized trial, 38 patients met the eligibility criteria. Six patients were exempted from this survey due to the following reasons: having neurotoxic therapy for advanced or recurrent breast cancer,Clinicopathological factors.FACT-NTx = functional assessment of cancer thera... | PMC10118320 |
3.2. Effect of cryotherapy on the incidence of persistent CIPN | cancer, CIPN | REGRESSION, CANCER | In all 38 patients, persistent CIPN was demonstrated in 10 (26.3%). The incidence of persistent CIPN was 15.8% and 36.8% in the cryotherapy and control group, respectively, indicating a numerically but not significantly lower incidence of persistent CIPN in the cryotherapy group compared with the control group (A multi... | PMC10118320 |
4. Discussion | SWOG, breast cancer, Taxane-induced CIPN, neuropathy, CIPN, taxane-induced CIPN, neurotoxic, diabetes | NEUROPATHY, BREAST CANCER, ADVERSE EVENT, REGRESSION, DIABETES | In this ancillary analysis of a previous randomized trial investigating the preventive effect of cryotherapy on weekly paclitaxel-induced CIPN in breast cancer patients, cryotherapy resulted in substantially lower incidence of early CIPN and a numerical decrease in the incidence of persistent CIPN at more than 1 year a... | PMC10118320 |
4.1. Study limitations | CIPN | First, the small sample size and unplanned nature of the ancillary analysis without statistical power limit the strength and clinical impact of our findings. Second, the study assessment of persistent CIPN was based on a subjective patient questionnaire. Objective evaluation, such as the Semmes-Weinstein monofilament t... | PMC10118320 | |
5. Conclusion | CIPN, breast cancer | BREAST CANCER | In conclusion, we demonstrated that cryotherapy reduced the incidence of persistent CIPN numerically and ≥ age 66 was a risk factor for persistent CIPN in breast cancer patients receiving weekly paclitaxel-based chemotherapy. A prospective randomized trial with a long-term period is needed to confirm the preventive eff... | PMC10118320 |
Abbreviations: | breast cancer, cancer, peripheral neuropathy, Cancer | BREAST CANCER, CANCER, PERIPHERAL NEUROPATHY, CANCER | chemotherapy-induced peripheral neuropathyfunctional assessment of cancer therapy-neurotoxicityThe authors have no funding and conflicts of interest to disclose.This study was endorsed by the Ethics Committee of the National Hospital Organization of Kure Medical Center and Chugoku Cancer Center (Approval number 28–70) ... | PMC10118320 |
References | PMC10118320 | |||
Background | pectoralis nerve block II, bleeding | BLEEDING | Classic neuraxial techniques, such as thoracic epidural anesthesia, or alternative approaches like the paravertebral block, are not indicated in cardiac surgery due to increased bleeding risk. To provide satisfactory analgesia without the need for excessive opioid use, novel ultrasound techniques gained popularity and ... | PMC10476350 |
Methods | In a single center, prospective, triple-blinded, two-group randomized trial, 60 patients undergoing elective, unilateral minimal invasive cardiac surgery will be randomized to receive a PECS II with 30 ml of ropivacaine 0.5% (intervention group) or sodium chloride 0.9% (placebo group). The primary outcome parameter is ... | PMC10476350 | ||
Discussion | postoperative pain | This prospective randomized, controlled, and triple-blinded trial aims to assess if a PECS II with ropivacaine 0.5% helps to decrease the opioid demand in the first 24 h and increases postoperative pain control after minimally invasive cardiac surgery. | PMC10476350 | |
Keywords | PMC10476350 | |||
Administrative information | InnsbruckInnrain, AustriaJohannes |
Elisabeth HoernerDepartment of Anaesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Anichstrasse 35, 6020 AustriaOttokar StundnerDepartment of Anaesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Anichstrasse 35, 6020 AustriaFelix Naegele (corresponding author)Departme... | PMC10476350 | |
Introduction | PMC10476350 | |||
Background and rationale {6a} | pain | MINOR, COMPLICATION | A multidisciplinary approach in perioperative care is crucial for improving patient recovery after major surgery. The so-called Enhanced Recovery After Surgery (ERAS) is an evidence-based protocol ranging from preoperative patient optimization to intra- and postoperative strategies aiming to improve clinical outcomes a... | PMC10476350 |
Objectives {7} | SECONDARY | The primary objective of this trial is to evaluate the efficacy of the PECS II block in patients undergoing unilateral MICS expressed as the reduction in the overall opioid demand given as intravenous MME during the first 24 h after extubation.The secondary objective of this trial is to evaluate the effect of the PECS ... | PMC10476350 | |
Trial design {8} | This is an investigator-initiated single-center prospective, triple-blinded, two-group, randomized trial with two treatment groups. | PMC10476350 | ||
Methods: participants, interventions, and outcomes | PMC10476350 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.